Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$9.45
-2.4%
$12.04
$2.53
$14.69
$762.49M2.141.12 million shs1.35 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$11.15
+0.8%
$8.93
$3.90
$14.67
$942.58M1.54784,045 shs552,486 shs
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$5.38
+4.9%
$3.94
$1.94
$5.65
$270.82M0.38379,417 shs305,600 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$14.32
$12.56
$9.03
$17.70
$997.86M1.19573,033 shs339,890 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
-2.38%-14.71%-29.69%+31.43%+240.54%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
+0.81%+1.55%+19.76%+115.04%+4.30%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
+4.87%+22.55%+40.10%+106.92%+15.20%
Zymeworks Inc. stock logo
ZYME
Zymeworks
0.00%+11.18%+14.74%+15.02%+39.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
1.6605 of 5 stars
3.50.00.00.03.00.00.0
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4.299 of 5 stars
4.51.00.04.40.03.30.6
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.4007 of 5 stars
3.54.00.04.22.61.70.6
Zymeworks Inc. stock logo
ZYME
Zymeworks
3.0177 of 5 stars
3.54.00.00.02.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
3.00
Buy$13.2239.89% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
3.00
Buy$18.5766.56% Upside
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$14.00160.22% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0046.65% Upside

Current Analyst Ratings Breakdown

Latest SCPH, ZYME, ORIC, and NAGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
7/3/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$13.00
6/23/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
6/10/2025
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $16.00
6/6/2025
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $23.00
5/29/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
5/27/2025
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$13.00
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/6/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.00
5/6/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$99.60M7.47$0.06 per share163.65$0.60 per share15.75
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.45 per shareN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$36.33M7.82N/AN/A$0.27 per share19.93
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M10.69N/AN/A$6.63 per share2.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$8.55M$0.1755.59N/A13.07%19.06%12.20%N/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)

Latest SCPH, ZYME, ORIC, and NAGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.30N/AN/AN/A$15.41 millionN/A
8/11/2025Q2 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.46N/AN/AN/AN/AN/A
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52N/AN/AN/A$17.18 millionN/A
5/14/2025Q1 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
5/5/2025Q1 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.51-$0.42+$0.09-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
N/A
3.66
3.12
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
12.00
12.00
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.86
5.48
4.61
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
15.41%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
95.05%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
9.39%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
5.55%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.78%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
12078.77 million71.37 millionN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8085.22 million80.49 millionOptionable
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3052.79 million50.27 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.68 million67.56 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Niagen Bioscience stock logo

Niagen Bioscience NASDAQ:NAGE

$9.45 -0.23 (-2.38%)
As of 07/22/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$11.15 +0.09 (+0.81%)
Closing price 07/22/2025 04:00 PM Eastern
Extended Trading
$10.95 -0.20 (-1.79%)
As of 07/22/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$5.38 +0.25 (+4.87%)
Closing price 07/22/2025 04:00 PM Eastern
Extended Trading
$5.34 -0.04 (-0.65%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$14.32 0.00 (0.00%)
Closing price 07/22/2025 04:00 PM Eastern
Extended Trading
$14.25 -0.07 (-0.48%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.